Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy

References

• World Health Organization2017Hepatitis C (Fact sheet No. 164) Web. October 2017. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/Accessed November 15, 2017
   Google Scholar
• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• GhanyMGStraderDBThomasDLSeeffLBAmerican Association for the Study of Liver DiseasesDiagnosis, management, and treatment of hepatitis C: an updateHepatology20094941335137419330875
   PubMed Web of Science ®Google Scholar
• KiserJJFlexnerCDirect-acting antiviral agents for hepatitis C virus infectionAnnu Rev Pharmacol Toxicol20135342744923140245
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARBorgiaFZappuloECastaldoGBorgiaGMK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infectionExpert Opin Investig Drugs2014235719728
   PubMed Web of Science ®Google Scholar
• CornbergMMannsMPNew kids on the block – step by step to an ideal HCV therapyLancet201538599731050105225468162
   PubMed Web of Science ®Google Scholar
• LawitzESulkowskiMSGhalibRSimeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyLancet201438499561756176525078309
   PubMed Web of Science ®Google Scholar
• SulkowskiMSGardinerDFRodriguez-TorresMAI444040 Study GroupDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionN Engl J Med2014370321122124428467
   PubMed Web of Science ®Google Scholar
• MannsMPolSJacobsonIMHALLMARK-DUAL Study TeamAll-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyLancet201438499541597160525078304
   PubMed Web of Science ®Google Scholar
• AfdhalNZeuzemSKwoPION-1 InvestigatorsLedipasvir and sofosbuvir for untreated HCV genotype 1 infectionN Engl J Med2014370201889189824725239
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKRNelsonDRION-2 InvestigatorsLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med2014370161483149324725238
   PubMed Web of Science ®Google Scholar
• FeldJJKowdleyKVCoakleyETreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171594160324720703
   PubMed Web of Science ®Google Scholar
• ShahUJayneCChackalamannilSNovel quinoline-based P2-P4 macrocyclic detivatives as pan-genotypic HCV NS3/4a protease inhibitorsACS Med Chem Lett20145326426924900818
   PubMed Web of Science ®Google Scholar
• PetryASFraserIPO’MaraESafety and antiviral activity of MK-5172, a next generation HCV N53/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patientsHepatology2011544531A
   Google Scholar
• SummaVLudmererSWMcCauleyJAMK-5172, a selective inhibitor of hepatitis C Virus NS3/4a protease with broad activity across genotypes and resistant variantsAntimicrob Agents Chemother201456841614167
   Web of Science ®Google Scholar
• CoburnCAMeinkePTChangWDiscovery of MK-8742: an HCV NS5A inhibitor with broad genotype activityChemMedChem20138121930194024127258
   PubMed Web of Science ®Google Scholar
• BrainardDMPetryAAndersonMSSafety, tolerability, and pharmacokinetics after single and multiple doses of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in healthy subjectsHepatology2010521216A1217A20803561
   PubMed Web of Science ®Google Scholar
• CaroLAndersonMDuLPharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis C virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 HCV –infected patientsHepatology20115441005A
   Google Scholar
• JacobsonIPoordadFFirpi-MorellREfficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1 infected patients with Child-Pugh class B cirrhosis (C-SALT). [EASL abstract O008]J Hepatol201562Suppl 2S193S194
   Web of Science ®Google Scholar
• MannsMVierlingJMBaconBRHigh sustained viral response at 12-and 24-week follow-up of MK-5172 with pegylated interferon alfa-2b and ribavirin (PR) in HCV genotype 1 treatment-naive non-cirrhotic patientsJ Hepatol201358S30
   Web of Science ®Google Scholar
• HoweAYBlackSCurrySVirologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis c virus genotype 1 infectionClin Infect Dis201459121657166525266289
   PubMed Web of Science ®Google Scholar
• LaggingMBrownAMantryPSGrazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trialJ Viral Hepat2016232808826353843
   PubMed Web of Science ®Google Scholar
• SulkowskiMHezodeCGerstoftJEfficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialLancet201538599731087109725467560
   PubMed Web of Science ®Google Scholar
• LawitzEGaneEPearlmanBEfficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialLancet201538599731075108625467591
   PubMed Web of Science ®Google Scholar
• GaneENahassRLuketicVEfficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. [EASL abstract P0776]J Hepatol201562Suppl 2S621
   Web of Science ®Google Scholar
• ZeuzemSGhalibRReddyKRGrazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trialAnn Intern Med2015163111325909356
   PubMed Web of Science ®Google Scholar
• RockstrohJKNelsonMKatlamaCEfficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialLancet HIV201528e319e32726423374
   PubMed Web of Science ®Google Scholar
• ButiMGordonSCZuckermanEGrazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGEClin Infect Dis2016621323626371152
   PubMed Web of Science ®Google Scholar
• RothDNelsonDRBruchfeldAGrazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyLancet2015386100031537154526456905
   PubMed Web of Science ®Google Scholar
• DoreGAlticeFLitwinAC-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. [AASLD abstract 40]Hepatology201563Suppl 1227A
   Google Scholar
• AsselahTReesinkHWGerstoftJHigh efficacy of grazoprevir and elbasvir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis. [AASLD abstract 251]Hepatology201563Suppl 1340A
   Google Scholar
• BrownAHézodeCZuckermanEC-SCAPE Study InvestigatorsEfficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE studyJ Viral Hepat Epub20171120
   Web of Science ®Google Scholar
• HézodeCColomboMBourlièreMC-EDGE IBLD Study InvestigatorsElbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III studyHepatology201766373674528256747
   PubMed Web of Science ®Google Scholar
• KwoPGaneEJPengCYEffectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment- experienced patients with chronic hepatitis C infectionGastroenterology20171521164175.e427720838
   PubMed Web of Science ®Google Scholar
• SperlJHorvathGHalotaWEfficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trialJ Hepatol20166561112111927542322
   PubMed Web of Science ®Google Scholar
• DusheikoGMMannsMPVierlingJMSafety and tolerability of grazoprevir/elbasvir in patients with chronic hepatitis C (HCV) infection: integrated analysis of phase 2–3 trials. [AASLD abstract 712]Hepatology201563Suppl 1562A
   Google Scholar
• LahserFLiuRBystolKA combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV repliconsHepatology201256236A
   Web of Science ®Google Scholar
• Zepatier™ (elbasvir/grazoprevir) [package insert]Whitehouse Station, NJMerck & Co., INC2016
   Google Scholar